HeadInvest LLC’s Rhythm Pharmaceuticals RYTM Stock Holding History

HeadInvest LLC’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-110	Closed	-$2.43K	–	594
2023 Q3	$2.43K	Buy	+110	New	+$2.46K	﹤0.01%	663

Other funds holding RYTM

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HeadInvest LLC's RYTM Position: Q4 2023 in Review

HeadInvest LLC sold out of Rhythm Pharmaceuticals (RYTM) in Q4 2023, closing a stake of 110 shares — an estimated $2.43K sold.

HeadInvest LLC first reported a position in RYTM in Q3 2023 and held it in 1 quarter. The position peaked at $2.43K in Q3 2023. 168 funds tracked by Wall St. Rank hold RYTM as of Q4 2023.

HeadInvest LLC reported no remaining Rhythm Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
HeadInvest LLC sold 110 Rhythm Pharmaceuticals shares in Q4 2023, an estimated $2.43K.
HeadInvest LLC first reported a position in Rhythm Pharmaceuticals in Q3 2023 and held it in 1 quarter.
HeadInvest LLC's Rhythm Pharmaceuticals position peaked at $2.43K in Q3 2023.
168 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q4 2023.

Based on HeadInvest LLC's 13F filing for Q4 2023, filed 12 Feb 2024.